Business
CytoMed Therapeutics announces Chairman’s Letter to the Company’s shareholders
SINGAPORE, Feb. 06, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”) today released a letter to shareholders
About this update from Cytomed Therapeutics Limited
[{"type":"text","content":"SINGAPORE, Feb. 06, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”) today released a letter to shareholders from the Chairman of the Company’s Board of Directors (the “Board”) as it welcomes the new year ahead of its full-year audited results announcement due by end-April, the full text of which is provided below. All shareholders of CytoMed are encouraged to read. Dear Shareholders, The Board of CytoMed wishes you a healthy and prosperous Year of the Snake. The snake’s ability to shed its skin is often compared to rebirth and renewal, representing adaptability and growth in Chinese mythology. The snake’s calm and quiet nature also embodies deep thought and strategic planning to embrace change and explore new possibilities. Its connection to transformation makes the Snake Year a relevant time for pursuing ambitious goals and doing things differently from others in the same bio-eco system. But first a quick recap. Based in Singapore and Malaysia, we are not in cancer targets discovery, a disease diagnostic company, a research biotech nor medical device company or a CDMO or CRO. Capitalizing on Asia’s low-cost infrastructure and talents, we make affordable GMP-grade immune cells to be infused into no-option patients to alleviate their cancers or autoimmune diseases. This operation continued to grow in 2024 especially with rising interest from doctors and researchers in donor-derived off-the-shelf allogeneic gamma delta T cells, a rare subset of cancer-killing T cells. We are proud of our accomplishments in 2024 driven by our dedicated employees and management team along with the effectiveness of our strategy. We achieved decent growth in our topline (based on the unaudited financials), product development, strategic partnership and internationalization. Details will be announced when available. Here is a quick recap of our accomplishments in 2024 and an outline of our direction for 2025: Clinical stage biopharma Late last year, CytoMed became a clinical stage biopharma with the first patient safely dosed in November 2024 under a clinical trial approved in Singapore. Termed ANGELICA trial, this is a first-in-human CAR T trial in the world involving CytoMed’s patented donor-derived allogeneic gamma delta T cells which express a chimeric antigen receptor (“CAR”) which can recognize ma...